Compare SVRE & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRE | ENVB |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | Israel | United States |
| Employees | 35 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.0M |
| IPO Year | N/A | 2000 |
| Metric | SVRE | ENVB |
|---|---|---|
| Price | $4.24 | $2.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.3K | ★ 7.7M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $1,793.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.56 |
| 52 Week High | $6.30 | $13.25 |
| Indicator | SVRE | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 36.71 |
| Support Level | $1.03 | $1.82 |
| Resistance Level | $4.92 | $4.48 |
| Average True Range (ATR) | 0.61 | 0.45 |
| MACD | -0.14 | -0.24 |
| Stochastic Oscillator | 7.39 | 0.58 |
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.